GLSI Company Profile and Key Details

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) closed at $18.57 USD, losing -$1.23 (-6.21%) from the previous close of $19.80. The stock is currently mid-range between its 52-week high and low $7.78 and $34.10. With a market capitalization of about $272.57 million, Greenwich LifeSciences, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~1.39). Key stats such as the average daily volume over the past year has been around 144.85 thousand shares, in line with its 52-week average. Headquartered in Stafford, TX, Greenwich LifeSciences, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Snehal S. Patel, the company employs approximately 13 people and listed since September 25, 2020. Greenwich LifeSciences, Inc. functions as a clinical-stage biopharmaceutical company, dedicated to developing innovative cancer immunotherapies.

Greenwich LifeSciences, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.46. This means the shares are trading above this model’s fair value.

Greenwich LifeSciences, Inc. trades at a P/E ratio of -11.82, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 51.31 reflecting a rich premium to book value. The P/FCF stands at -21.32, also below market averages. Compared to sector medians, Greenwich LifeSciences, Inc. P/S is trading at a discount to the sector, and the P/B is far higher than peers, underscoring the brand and earnings power premium investors assign to the stock.

Our AI price prediction model suggests that Greenwich LifeSciences, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -7.49%, with price expected at $17.18 by July 27, 2026, within a range of $15.07 to $19.11 3-Month Outlook: Projected rise of 110.82%, reaching $39.15 by October 08, 2026, with a range of $38.60 to $39.71. 1-Year Outlook: Projected gain of 19.71%, with price at $22.23 by July 13, 2027, within a range of $20.42 to $23.89.

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) shares are flat 1.33% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Greenwich LifeSciences, Inc. trading at a premium to the broader market with a P/E of -11.82. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $48.40, suggesting 160.64% upside. Our AI forecast model points to short-term weakness (-7.49% over two weeks), a medium-term rise (110.82% over three months), and a longer-term gain (19.71% over one year), with expected trading ranges indicating moderate volatility.